一个新的分期高剂量息性放射治疗方案,用于局部晚期鼻癌:一个病例报告
Saif Aljabab1,2, Amna Mohaimeed2, Firas AlMomen2
1Radiation Oncology Unit College of Medicine King Saud University, Riyadh, Saudi Arabia.
Case reports in oncological medicine
|October 11, 2024
概括
这项研究提出了一种新的高剂量息性放射治疗方案,用于晚期鼻恶性瘤 (SNMs). 该疗法在患有不可切除状细胞癌 (SCC) 的患者中提供了快速的症状缓解和瘤控制.
科学领域:
- 在瘤学瘤学.
- 辐射疗法 辐射疗法
- 头部和部癌症 头部和部癌症
背景情况:
- 鼻恶性瘤 (SNMs) 是罕见的,通常存在于局部发达的,不可切除的疾病.
- 广泛的SNMs的预后很差,需要缓和治疗策略.
- 对于不可切除的SNMs缺乏确立的高剂量息性放射治疗方案.
研究的目的:
- 报告一个先进的,不可切除的状细胞癌 (SCC) 的病例.
- 描述高剂量分疗程息性放射治疗方案的应用和结果.
- 为了评估这种疗法对快速瘤和症状控制的疗效.
主要方法:
- 一名33岁的男性患有晚期,无法切除的鼻腔状细胞癌 (SCC) 接受了息性放射治疗.
- 该疗法包括每天两次分为四个部分的14.80 Gy四次注射,然后每隔两周间隔每隔一天分为五个部分的30 Gy.
- 治疗用于迅速控制瘤和症状,以促进患者的旅行.
主要成果:
- 高剂量分疗程息性放射治疗导致了出色的临床反应.
- 在短时间内实现了显著的症状缓解.
- 由于有效的瘤和症状管理,患者能够安全返回他的祖国.
结论:
- 高剂量分疗程息性放射治疗可以成为管理先进,不可切除的鼻恶性瘤 (SNMs) 的有效策略.
- 这种方案提供了快速的症状控制和临床反应,改善了患者的生活质量.
- 需要进一步研究SNM中息性放射治疗的最佳剂量和分量.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...